PDF(Pubmed)
Abstract：
BACKGROUND: Testing for glucose-6-phosphate dehydrogenase (G6PD) deficiency is an important consideration regarding treatment for malaria. G6PD deficiency may lead to haemolytic anaemia during malaria treatment and, therefore, determining G6PD deficiency in malaria treatment strategies is extremely important.
METHODS: This report presents the results of a scoping review and evidence and gap map for consideration by the Guideline Development Group for G6PD near patient tests to support radical cure of Plasmodium vivax. This scoping review has investigated common diagnostic tests for G6PD deficiency and important contextual and additional factors for decision-making. These factors include six of the considerations recommended by the World Health Organization (WHO) handbook for guideline development as important to determining the direction and strength of a recommendation, and included \'acceptability\', \'feasibility,\' \'equity,\' \'valuation of outcomes,\' \'gender\' and \'human rights\'. The aim of this scoping review is to inform the direction of future systematic reviews and evidence syntheses, which can then better inform the development of WHO recommendations regarding the use of G6PD deficiency testing as part of malaria treatment strategies.
RESULTS: A comprehensive search was performed, including published, peer-reviewed literature for any article, of any study design and methodology that investigated G6PD diagnostic tests and the factors of \'acceptability\', \'feasibility,\' \'equity,\' \'valuation of outcomes,\' \'gender\' and \'human rights\'. There were 1152 studies identified from the search, of which 14 were determined to be eligible for inclusion into this review. The studies contained data from over 21 unique countries that had considered G6PD diagnostic testing as part of a malaria treatment strategy. The relationship between contextual and additional factors, diagnostic tests for G6PD deficiency and study methodology is presented in an overall evidence and gap, which showed that majority of the evidence was for the contextual factors for diagnostic tests, and the \'Standard G6PD (SD Biosensor)\' test.
CONCLUSIONS: This scoping review has produced a dynamic evidence and gap map that is reactive to emerging evidence within the field of G6PD diagnostic testing. The evidence and gap map has provided a comprehensive depiction of all the available literature that address the contextual and additional factors important for decision-making, regarding specific G6PD diagnostic tests. The majority of data available investigating the contextual factors of interest relates to quantitative G6PD diagnostic tests. While a formal qualitative synthesis of this data as part of a systematic review is possible, the data may be too heterogenous for this to be appropriate. These results can now be used to inform future direction of WHO Guideline Development Groups for G6PD near patient tests to support radical cure of P. vivax malaria.
METHODS: This report presents the results of a scoping review and evidence and gap map for consideration by the Guideline Development Group for G6PD near patient tests to support radical cure of Plasmodium vivax. This scoping review has investigated common diagnostic tests for G6PD deficiency and important contextual and additional factors for decision-making. These factors include six of the considerations recommended by the World Health Organization (WHO) handbook for guideline development as important to determining the direction and strength of a recommendation, and included \'acceptability\', \'feasibility,\' \'equity,\' \'valuation of outcomes,\' \'gender\' and \'human rights\'. The aim of this scoping review is to inform the direction of future systematic reviews and evidence syntheses, which can then better inform the development of WHO recommendations regarding the use of G6PD deficiency testing as part of malaria treatment strategies.
RESULTS: A comprehensive search was performed, including published, peer-reviewed literature for any article, of any study design and methodology that investigated G6PD diagnostic tests and the factors of \'acceptability\', \'feasibility,\' \'equity,\' \'valuation of outcomes,\' \'gender\' and \'human rights\'. There were 1152 studies identified from the search, of which 14 were determined to be eligible for inclusion into this review. The studies contained data from over 21 unique countries that had considered G6PD diagnostic testing as part of a malaria treatment strategy. The relationship between contextual and additional factors, diagnostic tests for G6PD deficiency and study methodology is presented in an overall evidence and gap, which showed that majority of the evidence was for the contextual factors for diagnostic tests, and the \'Standard G6PD (SD Biosensor)\' test.
CONCLUSIONS: This scoping review has produced a dynamic evidence and gap map that is reactive to emerging evidence within the field of G6PD diagnostic testing. The evidence and gap map has provided a comprehensive depiction of all the available literature that address the contextual and additional factors important for decision-making, regarding specific G6PD diagnostic tests. The majority of data available investigating the contextual factors of interest relates to quantitative G6PD diagnostic tests. While a formal qualitative synthesis of this data as part of a systematic review is possible, the data may be too heterogenous for this to be appropriate. These results can now be used to inform future direction of WHO Guideline Development Groups for G6PD near patient tests to support radical cure of P. vivax malaria.
摘要：
背景：检测葡萄糖-6-磷酸脱氢酶（G6PD）缺乏症是治疗疟疾的重要考虑因素。G6PD缺乏可能导致疟疾治疗期间的溶血性贫血，因此,确定G6PD缺乏症在疟疾治疗策略中非常重要。
方法：本报告提供了范围审查的结果以及证据和差距图，供G6PD近患者试验指南开发小组考虑，以支持间日疟原虫的根治。本范围审查调查了G6PD缺乏症的常见诊断测试以及决策的重要背景和其他因素。这些因素包括世界卫生组织（世卫组织）指南制定手册建议的六个考虑因素，这些因素对确定建议的方向和力度很重要，并包括“可接受性”，\'可行性，\'\'权益，结果的\'\'估值，\'\'性别\'和\'人权\'。本范围审查的目的是为未来的系统审查和证据综合提供指导，这可以更好地为制定世卫组织关于将G6PD缺乏症检测作为疟疾治疗战略一部分的建议提供信息。
结果：进行了全面搜索，包括出版,任何文章的同行评审文献，研究G6PD诊断测试和“可接受性”因素的任何研究设计和方法，\'可行性，\'\'权益，结果的\'\'估值，\'\'性别\'和\'人权\'。从搜索中确定了1152项研究，其中14人被确定有资格纳入本次审查。这些研究包含来自21个独特国家的数据，这些国家将G6PD诊断测试视为疟疾治疗策略的一部分。上下文和附加因素之间的关系，G6PD缺乏症的诊断测试和研究方法在总体证据和差距中提出，这表明大多数证据是诊断测试的背景因素，和标准G6PD(SD生物传感器)测试。
结论：本范围审查产生了动态证据和差距图，对G6PD诊断测试领域内的新兴证据具有反应性。证据和差距图提供了所有可用文献的全面描述，这些文献涉及对决策重要的背景和其他因素，关于特定的G6PD诊断测试。调查感兴趣的背景因素的大多数可用数据与定量G6PD诊断测试有关。虽然可以对这些数据进行正式的定性综合，作为系统审查的一部分，数据可能太异，这是不合适的。这些结果现在可用于为世卫组织G6PD指导发展小组的未来方向提供信息，以支持间日疟原虫的根治。
方法：本报告提供了范围审查的结果以及证据和差距图，供G6PD近患者试验指南开发小组考虑，以支持间日疟原虫的根治。本范围审查调查了G6PD缺乏症的常见诊断测试以及决策的重要背景和其他因素。这些因素包括世界卫生组织（世卫组织）指南制定手册建议的六个考虑因素，这些因素对确定建议的方向和力度很重要，并包括“可接受性”，\'可行性，\'\'权益，结果的\'\'估值，\'\'性别\'和\'人权\'。本范围审查的目的是为未来的系统审查和证据综合提供指导，这可以更好地为制定世卫组织关于将G6PD缺乏症检测作为疟疾治疗战略一部分的建议提供信息。
结果：进行了全面搜索，包括出版,任何文章的同行评审文献，研究G6PD诊断测试和“可接受性”因素的任何研究设计和方法，\'可行性，\'\'权益，结果的\'\'估值，\'\'性别\'和\'人权\'。从搜索中确定了1152项研究，其中14人被确定有资格纳入本次审查。这些研究包含来自21个独特国家的数据，这些国家将G6PD诊断测试视为疟疾治疗策略的一部分。上下文和附加因素之间的关系，G6PD缺乏症的诊断测试和研究方法在总体证据和差距中提出，这表明大多数证据是诊断测试的背景因素，和标准G6PD(SD生物传感器)测试。
结论：本范围审查产生了动态证据和差距图，对G6PD诊断测试领域内的新兴证据具有反应性。证据和差距图提供了所有可用文献的全面描述，这些文献涉及对决策重要的背景和其他因素，关于特定的G6PD诊断测试。调查感兴趣的背景因素的大多数可用数据与定量G6PD诊断测试有关。虽然可以对这些数据进行正式的定性综合，作为系统审查的一部分，数据可能太异，这是不合适的。这些结果现在可用于为世卫组织G6PD指导发展小组的未来方向提供信息，以支持间日疟原虫的根治。
